HomeWebcastEmerging Financing Alternatives for Life Sciences Companies: Opportunities and Pitfalls You Need to Know
Online CLE Life Sciences CLE

Emerging Financing Alternatives for Life Sciences Companies: Opportunities and Pitfalls You Need to Know

Live Webcast Date: Friday, October 04, 2019 from 12:00 pm to 1:30 pm (ET)
Finance (CPE)Health Care CLE & CPEPharmaceutical & Life Sciences CLE & CPELive Webcast
Listen Live/On-Demand
Add to Calendar 10/04/2019 12:00 pm 10/04/2019 1:30 pm America/New_York The Knowledge Group Webinar: Emerging Financing Alternatives for Life Sciences Companies: Opportunities and Pitfalls You Need to Know If you haven’t registered for this event please click here:https://www.theknowledgegroup.org/checkout/?add-to-cart=128091\r\n The emergence of real-world data and new digital technologies is fueling growth in the life sciences sector. This trend is resulting to increased investor interest and record funding. In this regard, life sciences businesses are now turning to alternative financing options to fund their growth. These include royalty financing, initial public offerings (IPOs), and collaborative arrangements. \n \nHowever, companies that enter these types of financing must be wary of potential drawbacks and reporting challenges. They must clearly understand and comply with the updated rules related to these alternatives. Counsel to businesses must develop an advanced strategic approach to leverage potentials and avoid legal issues. \n \nJoin a panel of key thought leaders and practitioners assembled by The Knowledge Group as they provide the audience with an in-depth discussion of these financing alternatives for the life sciences industry. Speakers will dig deeper as they analyze critical issues surrounding this topic. They will also offer practical tips and strategies to maximize its potentials in light of the recent regulatory developments. \n \nThis LIVE Webcast will discuss the following: \n \n \n Life Sciences Funding: Trends and Statistics \n Financing Alternatives \n Navigating Potentials \n Red Flags \n Risk Mitigation Strategies \n What Lies Ahead \n \n https://www.theknowledgegroup.org/webcasts/emerging-financing-alternatives/

Online CLE Life Sciences

Join us for this Knowledge Group Online CLE Life Sciences Webinar. The emergence of real-world data and new digital technologies is fueling growth in the life sciences sector. This trend is resulting to increased investor interest and record funding. In this regard, life sciences businesses are now turning to alternative financing options to fund their growth. These include royalty financing, initial public offerings (IPOs), and collaborative arrangements.

However, companies that enter these types of financing must be wary of potential drawbacks and reporting challenges. They must clearly understand and comply with the updated rules related to these alternatives. Counsel to businesses must develop an advanced strategic approach to leverage potentials and avoid legal issues.

Join a panel of key thought leaders and practitioners assembled by The Knowledge Group as they provide the audience with an in-depth discussion of these financing alternatives for the life sciences industry. Speakers will dig deeper as they analyze critical issues surrounding this topic. They will also offer practical tips and strategies to maximize its potentials in light of the recent regulatory developments.

This LIVE Webcast will discuss the following:

  • Life Sciences Funding: Trends and Statistics
  • Financing Alternatives
  • Navigating Potentials
  • Red Flags
  • Risk Mitigation Strategies
  • What Lies Ahead

Agenda

Christopher Swenson, Managing Director
Ankura
  • Traditional Equity
    • Common, Preferred
    • VCs, PE, Hedge Funds, Family Offices, Mutual Funds
    • Value: most permanent funding
    • Drawbacks: most dilution, longer time to funding
  • Debt
    • Venture Debt players, SVB
    • Non-traditional lenders, LSAF
    • Value is generally fast and easy to put in place
    • Drawbacks include debt and revenue participation, warrants, operating conditions, UCC-1
  • Royalty transactions
    • Egs include SWK Holdings, XOMA, a royalty aggregator
      • Aronora deal; $9MM with $6MM upfront and $3MM on milestones, in exchange for future royalties on blood clotting drug with Bayer collaboration but in Phase I
  • Form 10
    • Public filings but market makings very tough and does not come with capital; must be done separately via a PIPE
  • Reverse Merger
    • Can work opportunistically but not as a strategy
    • Generally very competitive, can come with shareholder baggage, can be protracted and often still need a PIPE
  • Reg CF
    • Start up Percolator; Wefunder; 3 years, $61MM raised for 194 companies
      • Great new access to small investors but limited to $1MM in 12 months; may not move the needle for biotech
  • Reg A+
    • Manhattan Street Capital; InSitu Biologics
      • More flexibility to raise between $3 and $50MM
      • But public filings required

Laurie A. Burlingame, Partner
Goodwin Procter LLP

Sara H. Shanti, Partner
Benesch Friedlander Coplan & Aronoff LLP
  • Health Care Regulatory Impact
    • Federal
    • State Variance
    • CPOM, Telemedicine, All-Payor Statutes
  • Compliance Program Guide
    • OIG Elements: Communication, Documentation, Monitoring, Officers, Training
    • Fraud, Waste, and Abuse (False Claims, AKS, Stark)
    • Executive Liability
  • Data Breaches/Security and PR
    • Data is Gold
    • International Storage/Transfer
    • Web of Alphabet Soup (HIPAA, BIPA, CCPA, GDPR)
  • Reimbursement and Future Valuation
    • Application Process
    • CMS Contractor/Vendor Requirements
    • Billion-dollar Lookbacks
    • Exclusion
    • FDA (Medical Devices)
  • Other Considerations
    • Start-ups and Limited Capital
    • Beta Rollouts
    • “Valuation+” (especially in tech)
    • Special Indemnity, “Takeouts,” Earn-outs, Clawbacks

Who Should Attend

  • Finance Lawyers and Advisers
  • Finance Executives
  • Accounting Executives
  • Finance Reporting Officers
  • Investment Advisers
  • Biotech, Pharma and Other Life Science Companies

Online CLE Life Sciences

Christopher Swenson, Managing Director
Ankura
  • Traditional Equity
    • Common, Preferred
    • VCs, PE, Hedge Funds, Family Offices, Mutual Funds
    • Value: most permanent funding
    • Drawbacks: most dilution, longer time to funding
  • Debt
    • Venture Debt players, SVB
    • Non-traditional lenders, LSAF
    • Value is generally fast and easy to put in place
    • Drawbacks include debt and revenue participation, warrants, operating conditions, UCC-1
  • Royalty transactions
    • Egs include SWK Holdings, XOMA, a royalty aggregator
      • Aronora deal; $9MM with $6MM upfront and $3MM on milestones, in exchange for future royalties on blood clotting drug with Bayer collaboration but in Phase I
  • Form 10
    • Public filings but market makings very tough and does not come with capital; must be done separately via a PIPE
  • Reverse Merger
    • Can work opportunistically but not as a strategy
    • Generally very competitive, can come with shareholder baggage, can be protracted and often still need a PIPE
  • Reg CF
    • Start up Percolator; Wefunder; 3 years, $61MM raised for 194 companies
      • Great new access to small investors but limited to $1MM in 12 months; may not move the needle for biotech
  • Reg A+
    • Manhattan Street Capital; InSitu Biologics
      • More flexibility to raise between $3 and $50MM
      • But public filings required

Laurie A. Burlingame, Partner
Goodwin Procter LLP

Sara H. Shanti, Partner
Benesch Friedlander Coplan & Aronoff LLP
  • Health Care Regulatory Impact
    • Federal
    • State Variance
    • CPOM, Telemedicine, All-Payor Statutes
  • Compliance Program Guide
    • OIG Elements: Communication, Documentation, Monitoring, Officers, Training
    • Fraud, Waste, and Abuse (False Claims, AKS, Stark)
    • Executive Liability
  • Data Breaches/Security and PR
    • Data is Gold
    • International Storage/Transfer
    • Web of Alphabet Soup (HIPAA, BIPA, CCPA, GDPR)
  • Reimbursement and Future Valuation
    • Application Process
    • CMS Contractor/Vendor Requirements
    • Billion-dollar Lookbacks
    • Exclusion
    • FDA (Medical Devices)
  • Other Considerations
    • Start-ups and Limited Capital
    • Beta Rollouts
    • “Valuation+” (especially in tech)
    • Special Indemnity, “Takeouts,” Earn-outs, Clawbacks

Online CLE Life Sciences

Online CLE Life Sciences

Christopher SwensonManaging DirectorAnkura

Chris Swenson is a Managing Director with Ankura Capital Advisors in San Francisco where he focuses on privately negotiated financings and strategic advisory for life sciences companies.

Prior to joining Ankura, Chris most recently served as the head of healthcare private equity placements with Piper Jaffray, where he led Piper’s efforts to provide privately-held healthcare companies with privately negotiated financings. He previously was a director with MTS Health Partners, a healthcare-focused merchant bank, where he focused on privately negotiated financings for life science companies. Earlier in his career, Chris held positions with Banc of America Securities, MicroCapital, and Robertson Stephens. He began his professional career as a corporate and transactional attorney. Chris holds a MBA in finance from the Kellogg School of Management at Northwestern University, a JD from Pepperdine University School of Law and an AB in economics from the University of California, Berkeley. He is a licensed attorney in California, Illinois and New York and holds FINRA Series 7 and 63 securities licenses.

Online CLE Life Sciences

Laurie A. BurlingamePartnerGoodwin Procter LLP

Online CLE Life Sciences

Sara H. ShantiPartnerBenesch Friedlander Coplan & Aronoff LLP

Sara Shanti is a partner in Benesch’s Health Care & Life Sciences Practice Group. Sara represents health care providers and technology companies in matters related to data privacy and security, health care regulatory compliance, and mergers and acquisitions.

Sara’s practice focuses on counseling clients on various digital health matters, including artificial intelligence, breach notification, mobile applications, and telemedicine. Sara’s experience includes advising clients on transferring data across multi-national borders, implementing compliance programs, launching health apps, and responding to federal investigations and security incidents, including ransomeware attacks. Her experience extends to consumer and minor patient rights, medical staff relationships, and transactional matters.


Click Here to Read Additional Material

Online CLE Life Sciences

Course Level:
   Intermediate

Advance Preparation:
   Print and review course materials

Method Of Presentation:
   Live Webcast

Prerequisite:
   General knowledge of corporate finance

Course Code:
   148208

NY Category of CLE Credit:
   Areas of Professional Practice

Total Credits:
    1.5 CLE

No Access

You are not logged in. Please or register to the event to gain access to the materials and login instructions.

About the Knowledge Group

The Knowledge Group

The Knowledge Group has been a leading global provider of Continuing Education (CLE, CPE) for over 13 Years. We produce over 450 LIVE webcasts annually and have a catalog of over 4,000 on-demand courses.

About the Knowledge Group

The Knowledge Group

The Knowledge Group has been a leading global provider of Continuing Education (CLE, CPE) for over 13 Years. We produce over 450 LIVE webcasts annually and have a catalog of over 4,000 on-demand courses.

Ankura Capital Advisors is the investment banking division of Ankura Consulting Group, a privately-held provider of business advisory and professional services. Based in Chicago, Ankura is majority owned by Madison Dearborn Partners and operates on a global basis.

Ankura Capital Advisors, LLC (Member FINRA, SIPC) offers investment banking services related to mergers, acquisitions, and divestitures as well as private placement capital raises:

  • M&A financial advisory for private and publicly traded companies, investment funds, and not-for-profit organizations
    • Buy-side advisory
    • Sell-side advisory (including dispositions of divisions and non-core assets)
  • Private placement transactions: placement agent services in connection with the sale of equity, debt, and hybrid securities to financial investors and strategic partners

Website: http://www.ankura.com/

Benesch is an AmLaw 200 business law firm and limited liability partnership with offices in Cleveland, Chicago, Columbus, San Francisco, Wilmington, Hackensack and Shanghai. The firm is known for providing highly sophisticated legal services to national and international clients that include public and private, middle market and emerging companies, as well as private equity funds, entrepreneurs, not-for-profit organizations, trusts and estates.

Chris Swenson is a Managing Director with Ankura Capital Advisors in San Francisco where he focuses on privately negotiated financings and strategic advisory for life sciences companies.

Prior to joining Ankura, Chris most recently served as the head of healthcare private equity placements with Piper Jaffray, where he led Piper’s efforts to provide privately-held healthcare companies with privately negotiated financings. He previously was a director with MTS Health Partners, a healthcare-focused merchant bank, where he focused on privately negotiated financings for life science companies. Earlier in his career, Chris held positions with Banc of America Securities, MicroCapital, and Robertson Stephens. He began his professional career as a corporate and transactional attorney. Chris holds a MBA in finance from the Kellogg School of Management at Northwestern University, a JD from Pepperdine University School of Law and an AB in economics from the University of California, Berkeley. He is a licensed attorney in California, Illinois and New York and holds FINRA Series 7 and 63 securities licenses.

Sara Shanti is a partner in Benesch’s Health Care & Life Sciences Practice Group. Sara represents health care providers and technology companies in matters related to data privacy and security, health care regulatory compliance, and mergers and acquisitions.

Sara’s practice focuses on counseling clients on various digital health matters, including artificial intelligence, breach notification, mobile applications, and telemedicine. Sara’s experience includes advising clients on transferring data across multi-national borders, implementing compliance programs, launching health apps, and responding to federal investigations and security incidents, including ransomeware attacks. Her experience extends to consumer and minor patient rights, medical staff relationships, and transactional matters.

Ultimate Value Annual Program

Bring a colleague for only $149, a savings of $50 per additional attendee.

  • Unlimited Access to Live & Recorded Webcasts
  • Instant Access to Course Materials
  • And More!

$199